Joe Biden Diagnosed Aggressive Prostate Cancer
Analysis based on 8 articles · First reported May 18, 2025 · Last updated May 19, 2025
The diagnosis of Joe Biden with aggressive prostate cancer is unlikely to have a direct, immediate impact on financial markets, as he is no longer a sitting president. However, it could indirectly affect the healthcare and pharmaceutical industries, particularly companies involved in cancer treatment and research, by potentially increasing public awareness and funding for such initiatives, especially given Joe Biden's past 'cancer moonshot' program.
Former US President Joe Biden, 82, has been diagnosed with an aggressive form of prostate cancer that has metastasized to his bones. The diagnosis was made on Friday after Joe Biden experienced increasing urinary symptoms, leading to the discovery of a prostate nodule and subsequent evaluation. His cancer has a Gleason score of 9, indicating a highly aggressive form, but it appears to be hormone-sensitive, allowing for effective management. Medical experts, including Dr. Matthew Smith of Massachusetts General Brigham Cancer Center and Dr. Herbert Lepor of NYU Langone Health, note that while incurable at this stage, treatments can extend life for several years. The news has prompted widespread support from political figures, including Donald Trump, Kamala Harris, and Barack Obama, who all expressed well wishes. Joe Biden's health has been a subject of scrutiny, particularly after his withdrawal from the 2024 election race following a debate performance. He previously spearheaded the 'cancer moonshot' program, aiming to halve cancer death rates.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard